QPPV.COM KNOWLEDGE ASSESSMENT

Pharmacovigilance in Older People: Geriatric Considerations Knowledge Assessment

Test your understanding of the concepts covered by Pharmacovigilance in Older People: Geriatric Considerations.

Question 1 of 10Pass mark: 80%

Question 1 of 10 How should a cluster of reports in older people identified through EudraVigilance be handled?

It should be treated as proof that the medicine caused an age-specific reaction. It should be disregarded because spontaneous reports cannot support signal management. It should enter the established signal-management process and undergo clinical assessment of chronology, alternatives, exposure and geriatric context. It should automatically lead to a contraindication in all older patients.

Question 2 of 10 An older patient receives an incorrect dose because a measuring device is difficult to use. What should the investigation primarily determine?

Whether the patient should automatically be classified as non-adherent. Whether the issue concerns the product, its presentation, instructions or the wider medication-use system. Whether all older patients require the same formulation. Whether medication errors are outside pharmacovigilance because no adverse reaction was intended.

Question 3 of 10 How can poor adherence be misinterpreted in pharmacovigilance?

It can be mistaken for treatment failure or for a new safety problem caused by the medicine. It always produces an overdose. It proves that the medicine has an unfavourable benefit-risk balance. It cannot affect the interpretation of an adverse event.

Question 4 of 10 Why can frailty create confounding in an observational safety analysis?

Frailty affects neither prescribing nor clinical outcomes. Frailty can increase both medicine exposure and the likelihood of serious outcomes, creating an apparent association. Frailty is a measure of medicine adherence only. Frailty prevents any meaningful use of real-world data.

Question 5 of 10 How should seriousness and functional consequence be considered in an older-patient case?

They are interchangeable concepts and require only one assessment. A clinically important functional decline may matter even if an event does not initially meet a conventional seriousness criterion, while seriousness must still be assessed separately. Only events resulting in death can have meaningful functional consequences. A hospitalisation always establishes that the medicine caused the event.

Question 6 of 10 Which statement best describes the regulatory status of geriatric pharmacovigilance in the EU framework discussed in the article?

It is governed by a dedicated final GVP geriatric chapter equivalent to the paediatric considerations. It is outside the scope of EU pharmacovigilance because older people are not considered a special population. It applies the general pharmacovigilance framework together with relevant scientific guidance on older populations. It is governed exclusively by national requirements rather than EU pharmacovigilance principles.

Question 7 of 10 Which responsibility remains with the MAH when specialist geriatric analysis is outsourced?

No responsibility remains once the vendor has received the data. The MAH must retain oversight of the pharmacovigilance system, understand significant findings and ensure appropriate actions are implemented. The vendor becomes the regulatory owner of the product benefit-risk profile. The MAH is responsible only for collecting patients' chronological ages.

Question 8 of 10 Why is post-authorisation pharmacovigilance particularly important for medicines used by older people?

Clinical trials always exclude every patient above 65 years. Routine practice may involve combinations, durations, comorbidities and frailty profiles that are under-represented in trials. Post-authorisation data are inherently free from confounding. Clinical trials cannot provide any information about pharmacokinetics or pharmacodynamics.

Question 9 of 10 Which evidence would be most useful for estimating whether an event occurs more often in older users of a medicine?

The absolute number of spontaneous reports by age alone. Exposure estimates, a suitable comparison population and a clearly defined outcome. A list of all medicines authorised for older people. A single detailed case report without information on exposure.

Question 10 of 10 Which example best demonstrates that formulation and usability can independently influence medicine safety?

A medicine has a well-characterised receptor target. A large tablet and unclear instructions increase swallowing or dosing errors despite the active substance being unchanged. A medicine is prescribed for a disease common in older people. A patient has a higher chronological age than the clinical-trial population.

Pharmacovigilance in Older People: Geriatric Considerations Knowledge Assessment

Cookie Settings